Team PhRMA Raises $100,000 for Leukemia/Lymphoma Research

Join our webcast on blood cancer research Monday, April 29 at 1 p.m. EDT

WASHINGTON, D.C. (April 26, 2013) – The Pharmaceutical Research and Manufacturers of America (PhRMA) has raised more than $100,000 to establish a new grant for blood cancer research. This Sunday, April 28, Team PhRMA will be participating in the inaugural Nike Women Half Marathon DC, benefiting the Leukemia & Lymphoma Society’s Team in Training program. About 60 colleagues from PhRMA will participate, half running or walking in the race, and the other half providing support and encouragement to race participants at the PhRMA water stop.

“We are so pleased to be part of this historic community effort in the fight to find cures for blood cancers,” said Josephine Martin, Team PhRMA captain and PhRMA’s executive vice president for Public Affairs. “Many of us at PhRMA have been personally impacted by a blood cancer, which resulted in a strong sense of camaraderie throughout the months of training and fundraising. We set high goals for ourselves, but as team captain, I take great pride in the selfless energy and passion demonstrated by my colleagues. We look forward to a great race this weekend.”

“Through their participation in Team In Training and the Nike Women’s Marathon Half DC, PhRMA employees have made a significant impact in the lives of blood cancer patients and their families, having raised more than $100,000 for LLS’s mission,” said Gabrielle Urquhart, LLS National Capital Chapter Executive Director. “A long-standing partner of the annual Leukemia Ball, we are thankful to PhRMA for expanding their involvement with LLS. Their commitment to helping patients living longer, healthier lives is one that we share, and together we are helping to make someday, today.”

Team PhRMA’s efforts – and accompanying support from a wide network of family members, friends and colleagues – are indicative of the determination, investment and partnership necessary to discover and develop new medicines. A new report released by PhRMA yesterday shows that America’s biopharmaceutical research companies are developing more than 240 medicines to treat leukemia, lymphoma, and other blood cancers.

To learn more about blood cancer research, please join PhRMA on Monday, April 29, 2013 at 1p.m. EDT for a live webinar featuring senior research experts in the field. The discussion will explore the exciting promise of medicines in the pipeline for blood cancers, the often incremental nature of cancer research and its role in improving patient health, barriers to future progress, and the importance of constructive partnerships to continued innovation.

Panel participants include Dr. Joe Camardo, senior vice president for global medical affairs, Celgene; Dr. Rick Winneker, senior vice president for research, Leukemia and Lymphoma Society; Dr. Salvatore Alesci, vice president for scientific affairs, PhRMA; and Jessica Melore, a cancer survivor. 

###

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested approximately $550 billion in the search for new treatments and cures, including an estimated $48.5 billion in 2012 alone.

Find PhRMA Online:

For information on how innovative medicines save lives, visit: http://www.innovation.org

For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org

For information on ensuring the flow of medicines during public health emergencies, visit http://www.rxresponse.org

More On PhRMA — powered by PhRMApedia